Undergoing lung transplant vs. receiving medical management alone led to greater 1-year survival in adults with medically ...

Utah Sen. Lee is pushing the Department of Health and Human Services to reclassify islet cells as organs so they can be used ...

Successful End-of-Phase 2 meeting with FDA supports advancement of tegoprubart into a global Phase 3 kidney transplantation trial, on track to ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Type 1 diabetes affects millions, and islet cell transplantation offers a promising ...

Continued progress toward starting SC451 Phase 1/2 trial, including GLP toxicology studies, SC451 process transfer to the contract manufacturer, and clinical trial readiness Continued progress toward ...

Sana Biotechnology Reports Second Quarter 2026 Financial Results And Business Updates. Continued progress toward starting SC451 Phase 1/2 trial, including GLP toxicology studies, SC451 process ...

Peer-Reviewed Letter to the Editor Describes Updated Long-Term Findings Consistent with Initial Trial Data Featured in NEJM Article Published in 2025 Seminal Study Successfully Achieved Primary and ...

Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions. Discover top stock picks and new investment opportunities through TipRanks' ...

– All 12 patients in study (100%) achieved insulin independence, producing their own insulin and no longer requiring exogenous insulin therapy to manage their T1D – All 12 patients also achieved an ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Advancing CNTY-813 as a potential functional cure in Type 1 Diabetes CNTY-813 iPSC-derived islet replacement therapy demonstrates durable in-vivo glucose control maintained for more than eight months ...

Islet transplantation hold promises as a cell therapy for managing type 1 diabetes, but its effectiveness remains limited due to early graft loss caused by hypoxia and associated stressors.